SCHEMBL3756580

SCHEMBL3756580

O=C(Cl)CCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
KMT2A Q03164 3/20 0.57
HPGD P15428 2/20 0.57
HSD17B10 Q99714 2/20 0.57
GAA P10253 1/20 0.57
POLB P06746 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.54
TDP1 Q9NUW8 1/20 0.54
CA12 O43570 1/20 0.53
CA9 Q16790 1/20 0.53
GLS O94925 1/20 0.53
HDAC8 Q9BY41 3/20 0.53
HDAC3 O15379 2/20 0.53
HDAC4 P56524 2/20 0.53
HDAC1 Q13547 2/20 0.53
HDAC7 Q8WUI4 2/20 0.53
HDAC2 Q92769 2/20 0.53
HDAC10 Q969S8 2/20 0.53
HDAC11 Q96DB2 2/20 0.53
HDAC6 Q9UBN7 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29642483 1.00 ALDH1A1 (0.57) ALDH1A1KMT2AHPGDHSD17B10GAA
SCHEMBL922425 0.89 ALDH1A1 (0.59) ALDH1A1KMT2AHPGDHSD17B10POLB
SCHEMBL2623697 0.87 HDAC8 (0.65) ALDH1A1KMT2AHPGDPOLBSMN1; SMN2
SCHEMBL5272078 0.86 HDAC8 (0.68) ALDH1A1KMT2AHPGDPOLBSMN1; SMN2
SCHEMBL8897691 0.86 HDAC8 (0.68) ALDH1A1KMT2AHPGDPOLBSMN1; SMN2
SCHEMBL14594063 0.84 KMT2A (0.60) ALDH1A1KMT2AHPGDHSD17B10GAA
SCHEMBL27432750 0.83 POLB (0.45) ALDH1A1KMT2AHPGDHSD17B10GAA
SCHEMBL30098360 0.82 CA12 (0.66) ALDH1A1KMT2AHPGDHSD17B10GAA
SCHEMBL135305 0.82 CA12 (0.66) ALDH1A1KMT2AHPGDHSD17B10GAA
SCHEMBL13276318 0.82 SMN1; SMN2 (0.52) ALDH1A1KMT2AHPGDGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4182322-B1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS CHIESI FARM SPA (IT) 2024-04-24 EP disclosed
US-20240116947-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-04-11 US disclosed
US-11802181-B2 Di-amine compound, and heat-resistant resin and resin composition using the same TORAY INDUSTRIES, INC. (JP) 2023-10-31 US disclosed
CN-114213335-B Carnosine intermediate and preparation and application of carnosine thereof 浙江湃肽生物股份有限公司 2023-08-15 CN disclosed
EP-4182322-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2023-05-24 EP disclosed
US-RE49481-E1 Compounds for the treatment and prophylaxis of respiratory syncytial virus disease HOFFMANN-LA ROCHE INC. (US) 2023-04-04 US disclosed
CN-110698481-B Heteroaryl pyridone and aza-pyridone amide compounds 豪夫迈·罗氏有限公司 2023-02-28 CN disclosed
CN-109906217-B Diamine compound, heat-resistant resin using same, and resin composition 东丽株式会社 2022-05-10 CN disclosed
CN-114213335-A Carnosine intermediate and preparation and application of carnosine 浙江湃肽生物有限公司 2022-03-22 CN disclosed
CN-114213503-A Synthesis method of snake venom-like tripeptide 上海予利生物科技股份有限公司 2022-03-22 CN disclosed
EP-0776892-A1 THIENYLAZOLE COMPOUND AND THIENOTRIAZOLODIAZEPINE COMPOUND YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1997-06-04 EP disclosed
WO-1996013485-A1 PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-05-09 WO disclosed
WO-1996007642-A1 PROCESS FOR PRODUCING A β-AMINO ALCOHOL F. HOFFMANN-LA ROCHE AG (DE) 1996-03-14 WO disclosed
US-4849436-A TREATMENT OF CARDIOVASCULAR DISORDERS NELSON RESEARCH & DEVELOPMENT CO. (US) 1989-07-18 US disclosed
EP-0259462-A1 1,4-DIHYDROPYRIDINES Whitby Research Incorporated (US) 1988-03-16 EP disclosed
WO-1987005512-A1 1,4-DIHYDROPYRIDINES NELSON RESEARCH AND DEVELOPMENT COMPANY (US) 1987-09-24 WO disclosed
EP-0197478-A1 Diphosphonic-acid derivatives, process for preparing them and medicines containing these compounds Roche Diagnostics GmbH (DE) 1986-10-15 EP disclosed
US-4548935-A Dihydropyridine anti-ischaemic and anti-hypertensive agents, compositions and use PFIZER INC. (US) 1985-10-22 US disclosed
EP-0150939-A1 Dihydropyridine anti-ischaemic and antihypertensive agents Pfizer Limited (GB) 1985-08-07 EP disclosed
US-3994940-A Preparation of 1-(2-(dimethylamino)ethyl)-6-phenyl-4H-5-triazolo(4,3-a)(1,4)benzodiazepines THE UPJOHN COMPANY (US) 1976-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116947-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS TGFBR1, ACVR1, TGFBR2 ALDH1A1 455/4885KMT2A 3553/4885HPGD 2150/4885
US-11802181-B2 Di-amine compound, and heat-resistant resin and resin composition using the same CAD, ARID2, SMC3 ALDH1A1 2539/4885KMT2A 1021/4885HPGD 3488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.